These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6896673)

  • 21. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progesterone receptor status of breast cancer metastases.
    Branković-Magić M; Janković R; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):55-60. PubMed ID: 11862473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of operative devascularization on estrogen and progesterone receptor levels in breast cancer specimens.
    Teicher I; Tinker MA; Auguste LJ; Laufer H; Stein TA; Wise L
    Surgery; 1985 Oct; 98(4):784-91. PubMed ID: 4049250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation of estrogen and progesterone receptor status in breast cancer.
    Alanko A
    Ann Clin Res; 1985; 17(1):10-4. PubMed ID: 4015025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
    J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supraclavicular lymph node metastases (SLM) from breast cancer as only site of distant disease: has radiotherapy any role?
    Pergolizzi S; Settineri N; Russi EG; Maisano R; Adamo V; Santacáterina A; Raffaele L; Marchetti G; Mesiti M
    Anticancer Res; 1997; 17(3C):2303-8. PubMed ID: 9216706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma.
    Jain V; Landry M; Levine EA
    Am Surg; 1996 Feb; 62(2):162-5. PubMed ID: 8554195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
    Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.